Kazia Therapeutics Limited (KZIA)

Market Cap	16.71M
Revenue (ttm)	1.66M
Net Income (ttm)	-17.87M
Shares Out	2.98M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,004
Open	5.67
Previous Close	5.63
Day's Range	5.50 - 6.01
52-Week Range	1.90 - 15.80
Beta	2.08
Analysts	Strong Buy
Price Target	20.00 (+256.51%)
Earnings Date	Nov 29, 2024

About KZIA

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 6, 1999
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZIA
• Website: https://www.kaziatherapeutics.com

Financial Performance

In 2024, Kazia Therapeutics's revenue was 2.49 million, an increase of 449089.19% compared to the previous year's 555. Losses were -26.78 million, 30.8% more than in 2023.

Financial numbers in AUD

Analyst Forecast

According to one analyst, the rating for KZIA stock is "Strong Buy" and the 12-month stock price forecast is $20.0.

Price Target

$20.0

(256.51% upside)

Analyst Consensus: Strong Buy